MétaCan
Menu
Back to cohort
Record W2425777806 · doi:10.3747/co.23.3120

Canadian Consensus: Inhibition of Alk-Positive Tumours in Advanced Non-Small-Cell Lung Cancer

2016· article· en· W2425777806 on OpenAlexafffundvenueabout
Barbara Melosky, Jason Agulnik, Roula Albadine, Shantanu Banerji, D. Gwyn Bebb, Drew Bethune, Normand Blais, Charles Butts, Parneet Cheema, Patrick Cheung, V. Cohen, Jean Deschênes, Diana N. Ionescu, Rosalyn A. Juergens, Suzanne Kamel‐Reid, Scott A. Laurie, Geoffrey Liu, W. Morzycki, Ming‐Sound Tsao, Zhaolin Xu, Vera Hirsh

Bibliographic record

VenueCurrent Oncology · 2016
Typearticle
Languageen
FieldMedicine
TopicLung Cancer Treatments and Mutations
Canadian institutionsPrincess Margaret Cancer CentreHôpital Saint-LucQueen Elizabeth II Health Sciences CentreUniversity of AlbertaOccupational Cancer Research CentreOttawa HospitalUniversity Health NetworkCancerCare ManitobaMcGill UniversityBC Cancer AgencyHôpital Notre-DameNova Scotia Health AuthorityRoyal Victoria HospitalSunnybrook Health Science CentreAlberta Cancer FoundationJewish General HospitalJuravinski Cancer CentreUniversity of Manitoba
FundersPfizer CanadaU.S. Food and Drug AdministrationAstraZeneca
KeywordsCrizotinibAnaplastic lymphoma kinaseCeritinibMedicineAlectinibLung cancerALK inhibitorInternal medicineOncologyCancer researchROS1Targeted therapyPopulationCancerAdenocarcinoma

Abstract

fetched live from OpenAlex

Anaplastic lymphoma kinase (alk) is an oncogenic driver in non-small-cell lung cancer (nsclc). Chromosomal rearrangements involving the ALK gene occur in up to 4% of nonsquamous nsclc patients and lead to constitutive activation of the alk signalling pathway. ALK-positive nsclc is found in relatively young patients, with a median age of 50 years. Patients frequently have brain metastasis. Targeted inhibition of the alk pathway prolongs progression-free survival in patients with ALK-positive advanced nsclc. The results of several recent clinical trials confirm the efficacy and safety benefit of crizotinib and ceritinib in this population. Canadian oncologists support the following consensus statement: All patients with advanced nonsquamous nsclc (excluding pure neuroendocrine carcinoma) should be tested for the presence of an ALK rearrangement. If an ALK rearrangement is present, treatment with a targeted alk inhibitor in the first-line setting is recommended. As patients become resistant to first-generation alk inhibitors, other treatments, including second-generation alk inhibitors can be considered.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.010
metaresearch head score (Gemma)0.016
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Review · Consensus signal: none
Teacher disagreement score0.562
Threshold uncertainty score0.871

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0100.016
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0020.003
Bibliometrics0.0020.003
Science and technology studies0.0050.003
Scholarly communication0.0030.002
Open science0.0080.002
Research integrity0.0220.015
Insufficient payload (model declined to judge)0.0100.009

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.028
GPT teacher head0.392
Teacher spread0.364 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations13
Published2016
Admission routes4
Has abstractyes

Explore more

Same venueCurrent OncologySame topicLung Cancer Treatments and MutationsFrench-language works237,207